Pfizer, Inc. — PFE
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $27.65 | $157.21B | 20.3 | 9.8 | 11.3% | 3.7% | $1.72 6.2% | 1.7 |
Latest Headlines
- · 2 Reasons to Like ZTS (and 1 Not So Much)
- · Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial
- · The Zacks Analyst Blog Highlights Meta Platforms, Netflix, Pfizer, SIFCO Industries and Altigen Communications
- · Amneal Pharmaceuticals Q4 Earnings Call Highlights
- · PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- · Pfizer’s New BRAFTOVI Approval Broadens Oncology Reach And Investor Debate
Revenue & Net Income
| Date | Revenue | Net_Income | EPS | Last_Updated | Revenue_Change | Net_Income_Change | EPS_Change | |
|---|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $41,651M | $9,159M | $1.73 | 2024-02-03 03:17:10 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $81,288M | $21,979M | $3.92 | 2026-02-27 22:04:12 | 95.2% | 140.0% | 126.6% |
| 2 | 2022-12-31 | $101,175M | $31,372M | $5.59 | 2026-02-27 22:04:12 | 24.5% | 42.7% | 42.6% |
| 3 | 2023-12-31 | $59,554M | $2,119M | $0.38 | 2026-02-27 22:04:12 | -41.1% | -93.2% | -93.2% |
| 4 | 2024-12-31 | $63,627M | $8,031M | $1.42 | 2026-02-27 22:04:12 | 6.8% | 279.0% | 273.7% |
| 5 | TTM 2025-12-31 | $45,022M | $9,418M | $1.36 | 2026-02-05 08:33:21 | -29.2% | 17.3% | -4.2% |
EPS
Forecasts
Y/Y % Change
PFE Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2026 | 2027 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 95.2% | 24.5% | -41.1% | 6.8% | -4.1% | -3.5% | 13.0% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 5 | 5 | |
| EPS Growth (%) | 140.0% | 42.7% | -93.2% | 279.0% | 110.3% | -4.7% | 79.0% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $81.3B | $24.1B | $13.8B | $12.7B | $5.2B |
| 2022 | $101.2B | $27.8B | $12.4B | $13.7B | $5.1B |
| 2023 | $59.6B | $17.1B | $10.9B | $14.8B | $6.3B |
| 2024 | $63.6B | $9.1B | $10.9B | $14.7B | $7.0B |
| TTM | $45.0B | $4.6B | $8.6B | $9.6B | $4.9B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 24.46 | 15.27 | -10.47 | 7.67 | -2.45 |
| 2023 | -41.14 | -38.52 | -12.18 | 8.00 | 24.21 |
| 2024 | 6.84 | -46.74 | 0.52 | -0.28 | 11.49 |
| TTM | -29.24 | -49.18 | -21.02 | -34.61 | -30.06 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $208,731M |
| 1 | Cash | $1,343M |
| 2 | Total Liabilities | $115,635M |
| 3 | Total Debt | $60,848M |
| 4 | Total Equity | $92,801M |
| 5 | Debt to Equity Ratio | 0.66 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $27.65 | 4.0% | Nicks Growth: 2% Nick's Expected Margin: 10% FINVIZ Growth: -9% |
Nicks: 8 Finviz: 3 |
Nick's: 0.820 | 3.5 | 20.3 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $1.36 EPS | TTM | $11.16 | -59.7% | $3.49 | -87.4% |
| $2.97 EPS | 2026 | $24.36 | -11.9% | $7.62 | -72.5% |
| $2.83 EPS | 2027 | $23.21 | -16.0% | $7.26 | -73.7% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 8.32% | 2.66% | 7.98% | 2.56% | 1.60% | 0.44% | 11.15% | 3.57% | 93.8% | 93.8% |
| 3 Years | 8.32% | 2.66% | 7.98% | 2.56% | 1.60% | 0.44% | 11.15% | 3.57% | 93.8% | 93.8% |
| 5 Years | 8.32% | 2.66% | 7.98% | 2.56% | 1.60% | 0.44% | 11.15% | 3.57% | 93.8% | 93.8% |
| 10 Years | 8.32% | 2.66% | 7.98% | 2.56% | 1.60% | 0.44% | 11.15% | 3.57% | 93.8% | 93.8% |